Disclosed herein are compounds of formula 1 where the substituents are as defined herein. Further disclosed is the use of the compounds in the manufacture of a medicament for the prophylaxis and/or treatment of chronic conditions selected from the group consisting of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). The compounds also have activity as FXR binding and activity modulating compounds and are therefore intended for use in the treatment of conditions such as liver diseases, inflammatory bowel diseases, diabetes, obesity, myocardial infarction, stroke and hyperproliferative disorders.
